Author
Listed:
- Ken-Ichiro Tanaka
(Faculty of Pharmacy, Keio University)
- Tomoaki Ishihara
(Faculty of Pharmacy, Keio University)
- Toshifumi Sugizaki
(Faculty of Pharmacy, Keio University)
- Daisuke Kobayashi
(Faculty of Pharmacy, Keio University)
- Yasunobu Yamashita
(Faculty of Pharmacy, Keio University)
- Kayoko Tahara
(Faculty of Pharmacy, Keio University)
- Naoki Yamakawa
(Faculty of Pharmacy, Keio University)
- Kumiko Iijima
(Medical Research Institute, Tokyo Medical and Dental University)
- Kaoru Mogushi
(Medical Research Institute, Tokyo Medical and Dental University)
- Hiroshi Tanaka
(Medical Research Institute, Tokyo Medical and Dental University)
- Keizo Sato
(Kyushu University of Health and Welfare)
- Hidekazu Suzuki
(Keio University School of Medicine)
- Tohru Mizushima
(Faculty of Pharmacy, Keio University)
Abstract
The clinical treatment of chronic obstructive pulmonary disease (COPD) requires not only an improvement of airflow by bronchodilation but also the suppression of emphysema by controlling inflammation. Here we screen a compound library consisting of clinically used drugs for their ability to prevent elastase-induced airspace enlargement in mice. We show that intratracheal administration or inhalation of mepenzolate bromide, a muscarinic antagonist used to treat gastrointestinal disorders, decreases the severity of elastase-induced airspace enlargement and respiratory dysfunction. Although mepenzolate bromide shows bronchodilatory activity, most other muscarinic antagonists do not improve elastase-induced pulmonary disorders. Apart from suppressing elastase-induced pulmonary inflammatory responses and the production of superoxide anions, mepenzolate bromide reduces the level of cigarette smoke-induced airspace enlargement and respiratory dysfunction. Based on these results, we propose that mepenzolate bromide may be an effective therapeutic for the treatment of COPD due to its anti-inflammatory and bronchodilatory activities.
Suggested Citation
Ken-Ichiro Tanaka & Tomoaki Ishihara & Toshifumi Sugizaki & Daisuke Kobayashi & Yasunobu Yamashita & Kayoko Tahara & Naoki Yamakawa & Kumiko Iijima & Kaoru Mogushi & Hiroshi Tanaka & Keizo Sato & Hide, 2013.
"Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease,"
Nature Communications, Nature, vol. 4(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms3686
DOI: 10.1038/ncomms3686
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms3686. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.